0000000000294229

AUTHOR

Etienne Sokal

0000-0001-5597-4708

showing 2 related works from this author

Improving the Techniques for Human Hepatocyte Transplantation: Report from a Consensus Meeting in London

2012

On September 6 and 7, 2009 a meeting was held in London to identify and discuss what are perceived to be current roadblocks to effective hepatocyte transplantation as it is currently practiced in the clinics and, where possible, to offer suggestions to overcome the blocks and improve the outcomes for this cellular therapy. Present were representatives of most of the active clinical hepatocyte transplant programs along with other scientists who have contributed substantial basic research to this field. Over the 2-day sessions based on the experience of the participants, numerous roadblocks or challenges were identified, including the source of cells for the transplants and problems with tra…

Transplantationbusiness.industryCellular differentiationMesenchymal stem celllcsh:RBiomedical Engineeringlcsh:MedicineCell Biologymedicine.diseaseBioinformaticsLiver regenerationCell therapyTransplantationLiver diseasemedicine.anatomical_structureHepatocyteImmunologymedicineStem cellbusiness
researchProduct

Persistence of Bactericidal Antibodies After Infant Serogroup B Meningococcal Immunization and Booster Dose Response at 12, 18 or 24 Months of Age

2016

Background: A serogroup B meningococcal vaccine (4CMenB) is licensed for infant use in countries including Canada, Australia and those of the European Union. Data on serum bactericidal antibody (hSBA) waning and the ideal timing of a "toddler" booster dose are essential to optimize vaccine utilization. Methods: An open-labeled, multicenter phase-2b follow-on European study conducted from 2009 to 2012. Participants previously receiving 4CMenB with routine vaccines at 2, 4 and 6 or 2, 3 and 4 months (246Con and 234Con) or at 2, 4 and 6 months intercalated with routine vaccines (246Int) received a booster dose at 12, 18 or 24 months. 4CMenB-naive "Control" participants aged 12, 18 or 24 months…

MaleMicrobiology (medical)Pediatricsmedicine.medical_specialtypaediatricpersistence of immunityImmunization SecondaryMeningococcal VaccinesMeningococcal vaccineBooster doseMeningitis MeningococcalNeisseria meningitidis Serogroup BPaediatric; Persistence of immunity; Serogroup B meningococcal vaccine; Serum bactericidal activity;Serum bactericidal activityserum bactericidal activity03 medical and health sciences0302 clinical medicine030225 pediatricsOutcome Assessment Health CaremedicineHumansmedia_common.cataloged_instance030212 general & internal medicineToddlerEuropean unionSerogroup B meningococcal vaccineImmunization Schedulemedia_commonMedicine(all)MeningococcalBooster (rocketry)business.industryVaccinationInfantbactericidal antibodiesmedicine.diseaseAntibodies BacterialEuropeVaccinationInfectious DiseasesImmunizationPaediatricChild PreschoolPediatrics Perinatology and Child HealthPersistence of immunityFemaleImmunizationbusinessMeningitisPediatric Infectious Disease Journal
researchProduct